Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Al-Azhar University

Status: Completed

Conditions: Herpetic Keratitis

Treatments: Drug: Acyclovir 400 MG; Drug: Ganciclovir (GCV)

Study type: Interventional

Funder types: Other

Identifiers

NCT06757907

Herpetic Keratitis

Details and patient eligibility

About

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Enrollment: 20 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with herpetic keratitis

Exclusion criteria

• Patients with known allergies to ganciclovir or acyclovir
• Severe ocular surface disease
• Those who have previously received antiviral therapy for herpetic keratitis within the last month

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

ganciclovir

Active Comparator group

Treatment:

Drug: Ganciclovir (GCV)

Systemic acyclovir

Active Comparator group

Treatment:

Drug: Acyclovir 400 MG